Three people going blind got one injection designed to make their old eye cells young again. Eight weeks later, two of them could see better. These are the first human results from age-reversal gene therapy.
In this episode of Health Longevity Secrets, Robert Lufkin MD breaks down the first-in-human data for ER-100, Life Biosciences’ epigenetic reprogramming therapy for glaucoma, presented October 8, 2026. You’ll learn how the OSK (Yamanaka factor) genes reset old retinal cells, what the safety data showed, what a 4-decibel visual field gain really means, how the therapy guards against cancer, and why three patients with no placebo group is a first step, not proof.
CHAPTERS:
00:00 — Introduction: First Human Results of Age Reversal.
00:28 — Recap: Human Age Reversal Has Begun.
00:44 — Glaucoma: Why Lost Vision Can’t Be Restored Today.
00:59 — Harvard 2020: OSK Genes Restore Vision in Old Mice.
01:29 — ER-100 Phase 1 Trial: First Human Results.
02:05 — ER-100 Safety Data Through Day 56
02:28 — 2 of 3 Glaucoma Patients Improved Their Vision.
02:48 — What a 4 dB Visual Field Gain Really Means.
03:42 — Does Cellular Reprogramming Cause Cancer?
04:17 — Will Age Reversal Arrive in Our Lifetime?
04:40 — Beyond Glaucoma: Macular Degeneration and Other Diseases.
04:59 — Honest Caveats: 3 Patients, No Placebo, Learning Effect.
06:04 — The Takeaway: The Race to Reverse Aging.
KEY TAKEAWAYS:
• ER-100 is the first therapy built to reverse cellular aging to be tested in people: 3 glaucoma patients, one eye injection at the lowest dose, plus doxycycline as the on-switch for 8 weeks.
• Safety was clean through day 56: no dose-limiting toxicities and no serious adverse events attributed to the gene therapy.
• 2 of 3 patients improved on the Humphrey visual field test, with at least 28% of tested points improving by more than 4 dB (about 2.5x dimmer light detected).
• An independent safety board approved tripling the dose for the next patients.
• The therapy leaves out c-Myc, a known cancer gene, and has an off switch; patients will be followed until about 2032.
• Big caveats: 3 patients, no placebo, open-label, a noisy test with a known learning effect, and a company presentation rather than a peer-reviewed paper.
STUDIES & SOURCES MENTIONED:
• Life Biosciences — First-in-human data from the ongoing Phase 1 trial of ER-100 (Oct 8, 2026) — https://www.lifebiosciences.com/life–…
• Lu et al., Nature 2020 — Reprogramming to recover youthful epigenetic information and restore vision — https://pubmed.ncbi.nlm.nih.gov/33268…
• ClinicalTrials.gov NCT07290244 — Evaluating ER-100 for Safety in Optic Neuropathies — https://clinicaltrials.gov/study/NCT0…
• Gillespie et al., Invest Ophthalmol Vis Sci 2003 — CIGTS visual field test-retest variability — https://pubmed.ncbi.nlm.nih.gov/12766…
• Business Insider — Silicon Valley billionaires and cellular reprogramming (Oct 2026) — https://www.businessinsider.com/billi…
• Previous episode — Human Age Reversal Has Begun — • Human Age Reversal Has Begun.
This video is for educational purposes only and is not medical advice.